Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inspire Medical Systems, Inc.INSP · Entity 1186 | Director | May 08, 2026 | May 11, 2026 |
| SURMODICS INCSRDX · Entity 72915 | Director | February 13, 2020 | February 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inspire Medical Systems, Inc.
Report date May 08, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,712 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Sale · Disposed 696 · Balance 27,712 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 3,000 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,000 |
SURMODICS INC
Report date February 13, 2020 · Filed February 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,210 |
Reported balance
After 2020-02-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-02-13 · Grant · Acquired 1,452 · Balance 9,210 F1: The amount beneficially owned includes 6,788 restricted stock units (RSUs) that vest on service-based vesting dates and 2,422 deferred stock units (DSUs) that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.58 · Expires 2027-02-13 | Direct | 4,218 |
Reported balance
After 2020-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-13 · Grant · Acquired 4,218 · Balance 4,218 F2: The stock options vest ratably on a monthly basis and become fully vested on February 13, 2021, the 12-month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The amount beneficially owned includes 6,788 restricted stock units (RSUs) that vest on service-based vesting dates and 2,422 deferred stock units (DSUs) that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends.
F2: The stock options vest ratably on a monthly basis and become fully vested on February 13, 2021, the 12-month anniversary of the grant date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ENTELLUS MEDICAL INC
Report date February 28, 2018 · Filed March 01, 2018
Section 16 reporting ended · disclosed 2018-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 1
1 source rowRow 1 · 2018-02-28 · Disposition to issuer · Disposed 5,441 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.36 · Expires 2024-11-09 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-28 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.38 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-28 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share.
F2: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
F3: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
F4: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 46,035 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2026 Filed May 11, 2026 20:05 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | SaleCommon Stock | 696 | $45.31 | $31,535.76 |
DisclosureSEC source: 0001104659-26-058634 · tm2614263-1_4seq1.xml · nonDerivative · entry 1 mcCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,712 Read SEC document |
| April 30, 2026 Filed May 4, 2026 22:19 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 3,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-055058 · tm2613528-2_4seq1.xml · nonDerivative · entry 1 mcCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,408 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:05 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | SaleCommon Stock | 1,200 | $139.00 | $166,800.00 |
DisclosureSEC source: 0001104659-25-118455 · tm2532785-1_4seq1.xml · nonDerivative · entry 1 mcCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,846 Read SEC document |
| November 28, 2025 Filed Dec 1, 2025 22:56 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | SaleCommon Stock | 2,000 | $127.48 | $254,960.00 |
DisclosureSEC source: 0001104659-25-117422 · tm2532514-1_4seq1.xml · nonDerivative · entry 1 mcCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,046 Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 22:06 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-25-057436 · tm2517412-1_4seq1.xml · derivative · entry 3 mcCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,296 Underlying: Common Stock · 4,000 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 22:06 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionCommon Stock | 4,000 | $16.00 | $64,000.00 |
DisclosureSEC source: 0001104659-25-057436 · tm2517412-1_4seq1.xml · nonDerivative · entry 1 mcCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option is fully vested and exercisable. Read SEC document |
| May 02, 2025 Filed May 5, 2025 23:31 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | SaleCommon Stock | 360 | $160.00 | $57,600.00 |
DisclosureSEC source: 0001104659-25-044673 · tm2514079-7_4seq1.xml · nonDerivative · entry 2 mcCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,046 Read SEC document |
| May 01, 2025 Filed May 5, 2025 23:31 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 1,266 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-044673 · tm2514079-7_4seq1.xml · nonDerivative · entry 1 mcCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,406 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| April 03, 2025 Filed Apr 3, 2025 20:30 UTC | NEVRO CORP NVRO · Entity 12422 | Disposition to issuerCommon Stock | 46,035 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-050474 · ownership.xml · nonDerivative · entry 1 mcCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2 · price: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. Read SEC document |
| September 09, 2024 Filed Sep 11, 2024 21:02 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | SaleCommon Stock | 800 | $220.00 | $176,000.00 |
DisclosureSEC source: 0001104659-24-098967 · tm2423831-2_4seq1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,140 Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:19 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,518 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001104659-24-090124 · tm2421806-1_4seq1.xml · derivative · entry 4 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,518 shares Expires 2027-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:19 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,019 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001104659-24-090124 · tm2421806-1_4seq1.xml · derivative · entry 3 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,019 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 20:19 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionCommon Stock | 8,537 | $0.94 | $8,024.78 |
DisclosureSEC source: 0001104659-24-090124 · tm2421806-1_4seq1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2024 Filed May 28, 2024 22:56 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 19,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000265 · form4.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,035 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 23, 2024 or (ii) the next Annual Meeting following May 23, 2024, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 19,169 RSUs. Read SEC document |
| May 10, 2024 Filed May 13, 2024 20:30 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001104659-24-060582 · tm2414211-1_4seq1.xml · derivative · entry 3 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,019 Underlying: Common Stock · 2,500 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 10, 2024 Filed May 13, 2024 20:30 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionCommon Stock | 2,500 | $0.94 | $2,350.00 |
DisclosureSEC source: 0001104659-24-060582 · tm2414211-1_4seq1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2024 Filed May 6, 2024 22:05 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 716 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-057563 · tm2413647-1_4seq1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,903 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:37 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 7,500 | $22.88 | $171,633.00 |
DisclosureSEC source: 0001610717-23-000108 · form4.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,866 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $22.8500 to $22.8896, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 6,754 restricted stock units. Read SEC document |
| May 25, 2023 Filed May 30, 2023 21:16 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 6,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000075 · form4.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,366 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2023 or (ii) the next Annual Meeting following May 25, 2023, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 6,754 RSUs. Read SEC document |
| April 27, 2023 Filed May 1, 2023 23:48 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantCommon Stock | 669 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-054646 · tm2314266-4_4seq1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,187 F1 · shares: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock. The RSUs shall vest upon the earlier to occur of (a) the first anniversary of the date of grant or (b) the date that is immediately prior to the occurrence of a Change of Control (as defined in the Issuer's 2018 Incentive Award Plan), in each case subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:05 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001104659-23-035049 · tm2310036-1_4seq1.xml · derivative · entry 3 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,519 Underlying: Common Stock · 4,000 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. F2 · balance_after: The amount of options originally reported in the Reporting Person's Form 3 dated May 2, 2018 understated the number of shares of common stock underlying the option by one share. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:05 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | Exercise / conversionCommon Stock | 4,000 | $0.94 | $3,760.00 |
DisclosureSEC source: 0001104659-23-035049 · tm2310036-1_4seq1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2022 Filed May 28, 2022 01:12 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011892 · doc1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,612 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 26, 2022 or (ii) the next Annual Meeting following May 26, 2022, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 4,155 RSUs. Read SEC document |
| May 26, 2022 Filed May 28, 2022 01:01 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 4,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011889 · doc1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,612 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 26, 2022 or (ii) the next Annual Meeting following May 26, 2022, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 4,155 RSUs. Read SEC document |
| April 28, 2022 Filed May 11, 2022 00:46 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantStock Option (right to buy) · Derivative | 1,243 | $0.00 Strike: $211.29 | $0.00 |
DisclosureSEC source: 0001104659-22-058414 · tm2215111-2_4seq1.xml · derivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,243 Underlying: Common Stock · 1,243 shares Expires 2032-04-28 F1 · derivative.exercise_date: The option vests and becomes exercisable on April 28, 2023, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| May 25, 2021 Filed May 27, 2021 00:58 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011219 · doc1.xml · nonDerivative · entry 2 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,457 F2 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 25, 2021 or (ii) the next Annual Meeting following May 25, 2021, subject to the Reporting Person's continued service to the issuer. F3 · balance_after: Includes 1,167 RSUs. Read SEC document |
| May 24, 2021 Filed May 27, 2021 00:58 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 482 | $149.65 | $72,131.30 |
DisclosureSEC source: 0001567619-21-011219 · doc1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,290 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| April 29, 2021 Filed May 3, 2021 21:20 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantStock Option (right to buy) · Derivative | 1,175 | $0.00 Strike: $240.68 | $0.00 |
DisclosureSEC source: 0001104659-21-060326 · tm2114992-7_4seq1.xml · derivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,175 Underlying: Common Stock · 1,175 shares Expires 2031-04-29 F1 · derivative.exercise_date: The option vests and becomes exercisable on April 29, 2022, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| May 21, 2020 Filed May 26, 2020 18:31 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 1,020 | $126.50 | $129,030.00 |
DisclosureSEC source: 0001567619-20-011147 · doc1.xml · nonDerivative · entry 2 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,772 F3 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: Includes 1,376 restricted stock units. Read SEC document |
| May 21, 2020 Filed May 26, 2020 18:31 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 1,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011147 · doc1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,792 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2020 or (ii) the next Annual Meeting following May 21, 2020, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 1,376 restricted stock units. Read SEC document |
| April 30, 2020 Filed May 5, 2020 00:39 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantStock Option (right to buy) · Derivative | 3,501 | $0.00 Strike: $71.66 | $0.00 |
DisclosureSEC source: 0001104659-20-056421 · a4.xml · derivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,501 Underlying: Common Stock · 3,501 shares Expires 2030-04-30 F1 · derivative.exercise_date: The option vests and becomes exercisable on April 30, 2021, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 16:35 UTC | SURMODICS INC SRDX · Entity 72915 | GrantStock Option (right to buy) · Derivative | 4,218 | $0.00 Strike: $39.58 | $0.00 |
DisclosureSEC source: 0001209191-20-010161 · doc4.xml · derivative · entry 2 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,218 Underlying: Common Stock · 4,218 shares Expires 2027-02-13 F2 · derivative.exercise_date: The stock options vest ratably on a monthly basis and become fully vested on February 13, 2021, the 12-month anniversary of the grant date. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 16:35 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 1,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010161 · doc4.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,210 F1 · balance_after: The amount beneficially owned includes 6,788 restricted stock units (RSUs) that vest on service-based vesting dates and 2,422 deferred stock units (DSUs) that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends. Read SEC document |
| November 11, 2019 Filed Nov 14, 2019 00:23 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 800 | $104.35 | $83,480.00 |
DisclosureSEC source: 0001567619-19-021256 · doc1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,416 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · balance_after: Includes 2,913 restricted stock units. Read SEC document |
| May 20, 2019 Filed May 22, 2019 21:57 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 2,913 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-011866 · doc1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,216 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 20, 2019 or (ii) the next Annual Meeting following May 20, 2019, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 2,913 RSUs. Read SEC document |
| May 02, 2019 Filed May 6, 2019 22:01 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantStock Option (right to buy) · Derivative | 4,569 | $0.00 Strike: $49.96 | $0.00 |
DisclosureSEC source: 0001104659-19-027217 · a4.xml · derivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,569 Underlying: Common Stock · 4,569 shares Expires 2029-05-02 F1 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2020, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 18:38 UTC | SURMODICS INC SRDX · Entity 72915 | GrantStock Option (right to buy) · Derivative | 2,605 | $0.00 Strike: $55.24 | $0.00 |
DisclosureSEC source: 0001209191-19-010779 · doc4.xml · derivative · entry 2 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,605 Underlying: Common Stock · 2,605 shares Expires 2026-02-13 F2 · derivative.exercise_date: The stock options vest ratably on a monthly basis and become fully vested on February 13, 2020, the 12-month anniversary of the grant date. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 18:38 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 859 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-010779 · doc4.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,758 F1 · balance_after: The amount beneficially owned includes 5,336 restricted stock units (RSUs) that vest on service-based vesting dates and 2,422 deferred stock units (DSUs) that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 16:25 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 133 | $47.26 | $6,285.58 |
DisclosureSEC source: 0001209191-19-000948 · doc4.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,899 F1 · shares: The reporting person elected to receive vested deferred stock units (DSUs) in lieu of quarterly cash retainer payments. The DSUs are settled in shares of the issuer's common stock as described below. F2 · balance_after: The amount beneficially owned includes 4,477 restricted stock units (RSUs) that vest on service-based vesting dates and 2,422 deferred stock units (DSUs) that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 16:35 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 84 | $74.65 | $6,270.60 |
DisclosureSEC source: 0001209191-18-053183 · doc4.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,766 F1 · shares: The reporting person elected to receive vested deferred stock units (DSUs) in lieu of quarterly cash retainer payments. The DSUs are settled in shares of the issuer's common stock as described below. F2 · balance_after: The amount beneficially owned includes 4,477 restricted stock units (RSUs) that vest on service-based vesting dates and 2,289 deferred stock units (DSUs) that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends. Read SEC document |
| June 30, 2018 Filed Jul 3, 2018 09:39 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 114 | $55.20 | $6,292.80 |
DisclosureSEC source: 0001209191-18-040554 · doc4.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,682 F1 · shares: The reporting person elected to receive vested deferred stock units (DSUs) in lieu of quarterly cash retainer payments. The DSUs are settled in shares of the issuer's common stock as described below. F2 · balance_after: The amount beneficially owned includes 4,477 restricted stock units (RSUs) that vest on service-based vesting dates and 2,205 deferred stock units (DSUs) that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends. Read SEC document |
| May 21, 2018 Filed May 23, 2018 23:18 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 3,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025423 · doc1.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,303 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of May 21, 2018 or (ii) the next Annual Meeting following May 21, 2018, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 3,785 RSUs. Read SEC document |
| May 07, 2018 Filed May 10, 2018 01:19 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | PurchaseCommon Stock | 3,000 | $16.00 | $48,000.00 |
DisclosureSEC source: 0001104659-18-031865 · a4.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 3,000 Read SEC document |
| May 02, 2018 Filed May 10, 2018 01:19 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | GrantEmployee Stock Option (right to buy) · Derivative | 17,296 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-18-031865 · a4.xml · derivative · entry 3 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,296 Underlying: Common Stock · 17,296 shares Expires 2028-05-02 F1 · derivative.exercise_date: The option vests and becomes exercisable on May 2, 2019, subject to the Reporting Person's continuous service to the Issuer through such date. The option was erroneously included on the Reporting Person's Form 3 filed on May 2, 2018. Read SEC document |
| March 30, 2018 Filed Apr 3, 2018 16:58 UTC | SURMODICS INC SRDX · Entity 72915 | GrantCommon Stock | 165 | $38.05 | $6,278.25 |
DisclosureSEC source: 0001209191-18-023110 · doc4.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,568 F1 · balance_after: The amount beneficially owned includes 4,477 restricted stock units (RSUs) that vest on service-based vesting dates and 2,091 deferred stock units (DSUs) that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 19:52 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $10.62 Strike: $13.38 | $53,100.00 |
DisclosureSEC source: 0001235802-18-000024 · primary_doc.xml · derivative · entry 4 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-06-13 F4 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 19:52 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $5.74 Strike: $18.26 | $57,400.00 |
DisclosureSEC source: 0001235802-18-000024 · primary_doc.xml · derivative · entry 3 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-14 F3 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 19:52 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | $12.64 Strike: $11.36 | $189,600.00 |
DisclosureSEC source: 0001235802-18-000024 · primary_doc.xml · derivative · entry 2 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-11-09 F2 · derivative.exercise_date: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 19:52 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerCommon Stock, $0.001 par value | 5,441 | $24.00 | $130,584.00 |
DisclosureSEC source: 0001235802-18-000024 · primary_doc.xml · nonDerivative · entry 1 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 16:57 UTC | SURMODICS INC SRDX · Entity 72915 | GrantStock Option (right to buy) · Derivative | 5,275 | $0.00 Strike: $27.30 | $0.00 |
DisclosureSEC source: 0001209191-18-012497 · doc4.xml · derivative · entry 2 McCormick Shawn · CIK 0001454092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 5,275 shares Expires 2025-02-20 F2 · derivative.exercise_date: The award vests in full on February 20, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.